Impact of Dissected Lymph Node Count on PD-1 Inhibitors Efficacy in Postoperative Recurred NSCLC: A Multi-Institutional Retrospective Study
Chunxia Su,Hongsheng Deng,Juan Zhou,Hualin Chen,Xiuyu Cai,Ran Zhong,Feng Li,Bo Cheng,Caichen Li,Qingzhu Jia,Caicun Zhou,Jianxing He,René Horsleben Peterson,Gaetano Rocco,Alex Brunelli,Calvin S.H. Ng,Thomas A. D&aposAmico,Wenhua Liang,Bo Zhu
DOI: https://doi.org/10.2139/ssrn.3940270
2021-01-01
Abstract:Background: The feasibility and efficacy of PD-1 inhibitors for postoperative recurred NSCLC, and the immunological implications of lymph node resection remain poorly elucidated. This study assessed the PD-1 inhibitors efficacy in these patients, and further illustrate the impact of dissected lymph node (DLN) count on immunotherapy response.Methods: We retrospectively identified postoperatively recurred NSCLC patients who received PD-1 blockades-based treatments between 2016 and 2020 from 4 hospitals. The prognostic effects of clinic-pathological variables on progression-free survival (PFS) were analyzed. Multivariable Cox analysis were performed to assess the prognostic value of DLN count.Findings: A total of 144 patients, with a median recurrence-free survival of 23.0 (95%CI, 19.1-26.9) months, were included. With a median postoperative follow-up time of 14.3 months (95%CI: 11.0-17.6), the median PFS was 7.9 (95%CI: 4.1-11.7) months for all 144 patients; 11.7 (95%CI: 7.9-15.6) months for combination therapy subgroup, and 4.8 (95%CI: 3.1-6.4) months for monotherapy subgroup, respectively. In post-hoc analysis, 59 patients had DLN count ≤ 16 [median, IQR: 11, 7-13]; 66 had DLN count > 16 [median, IQR: 23, 19-29] at the initial surgery. Notably, DLN count ≤ 16 was significantly associated with prolonged PFS, with a hazard ratio (HR) of 0.26 (95%CI, 0.07-0.90; P=0.03) in primary cohort and 0.46 (95%CI, 0.22-0.96; P=0.04) in validation cohort in multivariable Cox analysis. Subgroup analysis validated the survival superiority of DLN count ≤ 16 in both local recurrence (Cox-adjusted HR: 0.62) and distant metastasis (Cox-adjusted HR: 0.64) subgroups; and the prognostic benefit of DLN count ≤ 16 was more significant in the monotherapy, no adjuvant treatment, pN1, female, and squamous carcinoma subgroups.Interpretation: PD-1 inhibitors were effective among postoperatively recurred NSCLC patients; restrictive LN dissection (DLN count ≤ 16) was associated with better efficacy. A strategy to prevent over-dissection and preserve immune-depending lymph nodes should be developed.Funding: None to declare. Declaration of Interest; None to declare. Ethical Approval: This study was reviewed and approved by the ethical committee of the First Affiliated Hospital of Guangzhou Medical University (National Center for Respiratory Medicine, China).